Monday, February 24, 2014 1:24:02 PM
larson1, a couple thoughts:
The really easy money has already been made (most probably). It was like shooting fish in a barrel for the first few days. Oversold, overbought, oversold, ... . Trading is going to be more difficult and less profitable going forward, barring important real news--good or bad. Longer-term the share price will be dependent on whether NNVC achieves its anticipated benchmarks, and the manner in which those benchmarks are achieved.
noretreat, is absolutely right to be critical of the seemingly slow progress NNVC is making. NNVC has a history of a deteriorating share price in the absence of significant news (not the typical PR we get on Monday/Friday). Also true, there are many potential catalysts which are in the works that can drive the price much higher. Barring recent events, NNVC has been a fair trading stock (sharpshooting technical--high and low points).
Risky trading too. Technical highs and lows are also potential breakout or breakdown points. I protect myself by diversification, taking manageable risks, by having cash available for opportunities and hedging, and by watching events closely.
One point I come to in regards to NNVC and trading: On an average day, why trade NNVC? There are so many better trading candidates out there. This of course bars recent trading opportunities facilitated by the high degree of volatility. I trade daily. I rarely trade NNVC.
Just me.
The really easy money has already been made (most probably). It was like shooting fish in a barrel for the first few days. Oversold, overbought, oversold, ... . Trading is going to be more difficult and less profitable going forward, barring important real news--good or bad. Longer-term the share price will be dependent on whether NNVC achieves its anticipated benchmarks, and the manner in which those benchmarks are achieved.
noretreat, is absolutely right to be critical of the seemingly slow progress NNVC is making. NNVC has a history of a deteriorating share price in the absence of significant news (not the typical PR we get on Monday/Friday). Also true, there are many potential catalysts which are in the works that can drive the price much higher. Barring recent events, NNVC has been a fair trading stock (sharpshooting technical--high and low points).
Risky trading too. Technical highs and lows are also potential breakout or breakdown points. I protect myself by diversification, taking manageable risks, by having cash available for opportunities and hedging, and by watching events closely.
One point I come to in regards to NNVC and trading: On an average day, why trade NNVC? There are so many better trading candidates out there. This of course bars recent trading opportunities facilitated by the high degree of volatility. I trade daily. I rarely trade NNVC.
Just me.
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
